Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,301–3,400 of 15,747
Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine
Polinski, J. M., Weckstein, A., Batech, M., Kabelac, C., Kamath, T., Harvey, R. A., Jain, S., Rassen, J. A., Khan, N., & Schneeweiss, S. (2021) · medRxiv · doi:10.1101/2021.09.10.21263385 · Cited by 32
“This is consistent with the age-dependent variation in VE observed in the ENSEMBLE trial and with evidence on the immune response to the BNT162b2 vaccine by age.(3,26,27) Results from our population-based study suggest that immunocompromised patients who are vaccinated with a single dose have slightly reduced yet stil…”
ResultEasdale, S., Shea, R. L., Ellis, L., Bazin, J., Davis, K., Dallas, F., Thistlethwayte, E., Ethell, M. E., Potter, M. N., Arias, C., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.07.011 · Cited by 31
Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery
Eygeris, Y., Henderson, M. I., Curtis, A. G., Jozić, A., Stoddard, J., Reynaga, R., Chirco, K. R., Su, G., Neuringer, M., Lauer, A. K., et al. (2024) · Small · doi:10.1002/smll.202400815 · Cited by 34
Gastrointestinal tract and viral pathogens
Jagirdhar, G. S. K., Pulakurthi, Y. S., Chigurupati, H. D., & Surani, S. (2023) · World Journal of Virology · doi:10.5501/wjv.v12.i3.136 · Cited by 36
COVID-19 vaccine hesitancy and acceptance in Mexico: a web-based nationwide survey
Ramonfaur, D., Hinojosa-Gonzalez, D. E., Rodriguez-Gomez, G. P., Iruegas-Nunez, D. A., & Flores-Villalba, E. A. (2021) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2021.133 · Cited by 33
“According to the most recent studies evaluating the efficacy of the Pfizer–BioNTech vaccine, an efficacy of more than 90% is estimated for most people currently receiving the vaccine (17).”
BackgroundSprengholz, P., Eitze, S., Korn, L., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.03.015 · Cited by 32
Bianchi, F. P., Germinario, C. A., Migliore, G., Vimercati, L., Martinelli, A., Lobifaro, A., Tafuri, S., Stefanizzi, P., Control Room Working Group, Amoruso, F., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab262 · Cited by 34
Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview
Rouatbi, N., McGlynn, T., & Al‐Jamal, K. T. (2022) · Biomaterials Science · doi:10.1039/d1bm01452h · Cited by 37
Larsen, S. E., Berube, B. J., Pecor, T., Cross, E., Brown, B. P., Williams, B. D., Johnson, E., Qu, P., Carter, L. P., Wrenn, S. P., et al. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113160 · Cited by 33
“We believe this combination of clinically qualified serology assays will be valuable in comparing responses from various vaccines (Polack et al., 2020; Keech et al., 2020; Sadoff et al., 2021; Erasmus et al., 2020; Folegatti et al., 2020), cutting-edge boost regimens (Logunov et al., 2021; Tanne,…”
Xia, H., He, Y.-R., Zhan, X.-Y., & Zha, G. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105668 · Cited by 35
Chevillard, C., Amen, A., Besson, S., Hannani, D., Bally, I., Dettling, V., Gout, E., Moreau, C., Buisson, M., Gallet, S., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.011 · Cited by 35
Woolf, K., McManus, I. C., Martin, C. A., Nellums, L. B., Guyatt, A. L., Melbourne, C., Bryant, L., Gogoi, M., Wobi, F., Al‐Oraibi, A., et al. (2021) · medRxiv · doi:10.1101/2021.04.26.21255788 · Cited by 32
Emerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors
Presti, S. L., Elajami, T. K., Reyaldeen, R. M., Anthony, C. M., Imazio, M., & Klein, A. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021685 · Cited by 35
Cui, X., Vervaeke, P., Gao, Y., Opsomer, L., Sun, Q., Snoeck, J., Devriendt, B., Zhong, Z., & Sanders, N. N. (2024) · npj Vaccines · doi:10.1038/s41541-024-00932-x · Cited by 33
Vaccinations in multiple sclerosis patients receiving disease-modifying drugs
Otero‐Romero, S., Ascherio, A., & Lebrun‐Frénay, C. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000929 · Cited by 33
SARS-CoV-2 vaccine-associated-tinnitus: A review
Ahmed, S. H., Waseem, S., Shaikh, T. G., Qadir, N. A., Siddiqui, S. A., Ullah, I., Waris, A., & Yousaf, Z. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103293 · Cited by 35
Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
Holden, I. K., Bistrup, C., Nilsson, A. C., Hansen, J. F., Abazi, R., Davidsen, J. R., Poulsen, M. K., Lindvig, S. O., Justesen, U. S., & Johansen, I. S. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13361 · Cited by 34
Sei, S., Ahadova, A., Keskin, D. B., Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Lipkin, S. M., & Kloor, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1147590 · Cited by 38
Haley, R. M., Padilla, M. S., El-Mayta, R. D., Joseph, R. A., Weber, J. A., Figueroa‐Espada, C. G., Mukalel, A. J., Ricciardi, A. S., Palanki, R., Geisler, H. C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16617 · Cited by 42
Emborg, H., Valentiner‐Branth, P., Schelde, A. B., Nielsen, K. F., Gram, M. A., Moustsen‐Helms, I. R., Chaine, M., Seidelin, U. H., & Nielsen, J. O. (2021) · medRxiv · doi:10.1101/2021.05.27.21257583 · Cited by 36
Tang, J., Rakshit, M., Chua, H. M., Darwitan, A., Nguyen, L. T. H., Muktabar, A., Venkatraman, S. S., & Ng, K. W. (2021) · Nanotechnology · doi:10.1088/1361-6528/ac2810 · Cited by 32
Targeted Delivery of mRNA with Polymer–Lipid Nanoparticles for In Vivo Base Editing
Chen, Q., Chang, Y., He, X., Ding, Y., Wang, R., Luo, R., Yuan, J., Chen, J., Zhong, G., Yang, H. Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14041 · Cited by 36
Xiang, T., Liang, B., Wang, H., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00795-5 · Cited by 32
“Although significant advances have been made in developing and applying different vaccines in clinical trials [1, 2], data are limited on the safety and efficacy of the inactivated vaccine in patients with chronic liver disease [3].”
BackgroundHennrich, A. A., Sawatsky, B., Santos-Mandujano, R., Banda, D. H., Oberhuber, M., Schopf, A., Pfaffinger, V., Wittwer, K., Riedel, C., Pfaller, C. K., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009064 · Cited by 30
Toniutto, P., Falleti, E., Cmet, S., Cussigh, A., Veneto, L., Bitetto, D., Fornasiere, E., Fumolo, E., Fabris, C., Sartor, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.015 · Cited by 40
Gene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 36
Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries
David, A. B., Diamant, E., Dor, E., Barnea, A., Natan, N., Levin, L., Chapman, S., Mimran, L. C., Epstein, E., Zichel, R., et al. (2021) · Molecules · doi:10.3390/molecules26113213 · Cited by 38
Abe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., et al. (2021) · doi:10.1101/2021.08.06.21261721 · Cited by 32
Okuyama, R. (2023) · Vaccines · doi:10.3390/vaccines11121737 · Cited by 47
Préta, L., Contejean, A., Salvo, F., Tréluyer, J., Charlier, C., & Chouchana, L. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15280 · Cited by 34
“To date, two mRNA vaccines, BNT162b2 (PfizerBioNTech) and mRNA-1273 (Moderna), have been approved.(1,2) Although these vaccines have a very good safety profile, postmarketing monitoring is key, especially during mass immunizations.”
BackgroundMonforte, A. D., Tavelli, A., Perrone, P. M., Zà, A., Razzini, K., Tomasoni, D., Bordoni, V., Romanò, L., Orfeo, N. V., Marchetti, G. C., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100914 · Cited by 33
“These results are in line with the data published by Polack et al.[4] and confirm the safety of this vaccine.”
InfluentialGross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan
Matsuzaki, K., Aoki, R., Nihei, Y., Suzuki, H., Kihara, M., Yokoo, T., Kashihara, N., Narita, I., & Suzuki, Y. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02157-x · Cited by 33
Saba, A. A., Adiba, M., Saha, P., Hosen, M. I., Chakraborty, S., & Nabi, A. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104703 · Cited by 38
Acceptance of COVID-19 Vaccination Among Health System Personnel
Parente, D. J., OJO, A. O., Gurley, T., LeMaster, J. W., Meyer, M., Wild, D., & Mustafa, R. A. (2021) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2021.03.200541 · Cited by 34
Improving the analysis of adverse event data in randomized controlled trials
Cornelius, V. R., & Phillips, R. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.12.023 · Cited by 27
The intestinal microbiota and improving the efficacy of COVID-19 vaccinations
Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32
Drury, R. E., Camara, S., Chelysheva, I., Bibi, S., Sanders, K. A., Felle, S., Emary, K. R. W., Phillips, D. J., Voysey, M., Ferreira, D. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47463-6 · Cited by 35
A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS‐CoV‐2 vaccine
Murdych, T. M. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13653 · Cited by 32
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia
Morawska, M. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13722 · Cited by 32
Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 32
“Second dose of vaccination was effective for some variants but not for Omicron The Pfizer mRNA vaccine shows 95% effectiveness against the ancestral strain, WK521.(12) However, some groups reported that NTs against the Beta and Kappa strains”
COVID-19 vaccination immune paresis in heart and lung transplantation
Aslam, S., Danziger‐Isakov, L. A., & Mehra, M. R. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.018 · Cited by 38
Ibrahim, H., Alkhatib, A., & Meysami, A. (2022) · Cureus · doi:10.7759/cureus.21176 · Cited by 34
“The United States Food and Drug Administration has thus far approved three different vaccines, those of which showed great efficacy and safety rates [1-3].”
BackgroundBshesh, K., Khan, W., Vattoth, A. L., Janjua, E., Nauman, A., Almasri, M., Ali, A. M., Ramadorai, V., Mushannen, B., Al-Subaie, M., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27599 · Cited by 34
Saliu, T. P., Umar, H. I., Ogunsile, O. J., Okpara, M. O., Yanaka, N., & Elekofehinti, O. O. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00273-5 · Cited by 37
“Most of these vaccines have demonstrated between 90 and 95% efficacy against SARS-CoV-2 [40, 41].”
BackgroundSalazar, P. M. D., Link, N., Lamarca, K., & Santillana, M. (2021) · Communications Medicine · doi:10.1038/s43856-021-00015-1 · Cited by 35
The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccinesPreprint
Liu, H., Wei, P., Zhang, Q., Aviszus, K., Linderberger, J., Yang, J. J., Liu, J., Chen, Z., Waheed, H., Reynoso, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.25.457692 · Cited by 32
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong
(2021) · doi:10.1101/2021.10.28.21265635 · Cited by 162
A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 33
“The exclusion criteria include individuals with (1) documented SARSCoV-2 infection, (2) high-risk infection history within 14 days before vaccination, (3) COVID-19 symptoms such as sore throat, fever, cough and shortness of breath.”
BackgroundGallud, A., Munson, M. J., Liu, K., Idström, A., Barriga, H. M. G., Tabaei, S. R., Aliakbarinodehi, N., Ojansivu, M., Lubart, Q., Doutch, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.20.457104 · Cited by 35
Makhamreh, A. K., Tavakoli, S., Fallahi, A., Kang, X., Gamper, H., Nabizadehmashhadtoroghi, M., Jain, M., Hou, Y., Rouhanifard, S. H., & Wanunu, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-72994-9 · Cited by 32
Immune Imprinting and Implications for COVID-19
Zhou, Z., Barrett, J., & He, X. (2023) · Vaccines · doi:10.3390/vaccines11040875 · Cited by 42
“The approved or authorized COVID-19 vaccines are developed by different platforms including mRNA [60,61], viral vectors that express full-length spike proteins [62–64], inactivated whole virus [65–67] or purified spike proteins [68,69].”
BackgroundScaria, P. V., Roth, N., Schwendt, K., Muratova, O. V., Alani, N., Lambert, L., Barnafo, E. K., Rowe, C. G., Zaidi, I., Rausch, K. M., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00783-y · Cited by 43
Prompetchara, E., Ketloy, C., Alameh, M., Tharakhet, K., Kaewpang, P., Yostrerat, N., Pitakpolrat, P., Buranapraditkun, S., Manopwisedjaroen, S., Thitithanyanont, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37795-0 · Cited by 32
Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination
Aydoğan, B. İ., Ünlütürk, U., & Cesur, M. (2022) · Endocrine · doi:10.1007/s12020-022-03130-8 · Cited by 36
“During COVID-19 pandemic, worsening of hyperglycemia, precipitation of ketosis, and ketoacidosis have been reported in diabetic patients [21, 22].”
InfluentialZhou, R., To, K. K., Peng, Q., Chan, J. M., Huang, H., Yang, D., Lam, B. H. S., Chuang, V. W., Cai, J., Liu, N., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.720 · Cited by 36
Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials
Calzetta, L., Ritondo, B. L., Coppola, A., Matera, M. G., Daniele, N. D., & Rogliani, P. (2021) · Vaccines · doi:10.3390/vaccines9040341 · Cited by 32
Papageorgiou, V. Ε., & Tsaklidis, G. M. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.112914 · Cited by 31
“05, considering that the average protection rate from the vaccination is 95 % [33].”
Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance
Shkoda, A. S., Gushchin, V. А., Ogarkova, D. A., Stavitskaya, S. V., Oe, O., Kuznetsova, N. A., Keruntu, E. N., Pochtovyi, A. A., Pukhov, A. V., Kleymenov, D. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10060938 · Cited by 39
“The emergence of several vaccines with high efficacy for COVID-19 prevention was the greatest success of the first pandemic year, including Sputnik V (Gamaleya Research Centre) [1], mRNA-1273 (Moderna) [2], BNT162b2 (Pfizer) [3], and ChAdOx1 nCoV-19 Vaccine AZD1222 (Oxford, UK, AstraZeneca) [4].”
BackgroundBouattour, N., Hdiji, O., Sakka, S., Fakhfakh, E., Moalla, K. S., Daoud, S., Farhat, N., Damak, M., & Mhiri, C. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05733-x · Cited by 34
“Our bodies recognize this protein as an invader and produce antibodies against it [4].”
BackgroundNeutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30
Altarawneh, H., Chemaitelly, H., Ayoub, H., Hasan, M. R., Coyle, P., Yassine, H., Khatib, H. A., Benslimane, F., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.07.11.22277448 · Cited by 20
Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach
Martínez‐Rodríguez, D., González‐Parra, G., & Villanueva, R. J. (2021) · Epidemiologia · doi:10.3390/epidemiologia2020012 · Cited by 34
Bassi, J., Giannini, O., Silacci-Fregni, C., Pertusini, L., Hitz, P., Terrot, T., Franzosi, Y., Muoio, F., Saliba, C., Meury, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263328 · Cited by 35
“This difference can be explained by the lower mRNA amount provided by one dose of BNT162b2 compared to mRNA-1273 [11, 12].”
BackgroundSankaradoss, A., Jagtap, S., Nazir, J., Moula, S. E., Modak, A., Fialho, J., Iyer, M., Shastri, J. S., Dias, M., Gadepalli, R., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.013 · Cited by 32
“Among other technologies, nucleic acid vaccines have emerged as a rapid and versatile platform for an emergency, which is why these are among the very first COVID-19 vaccines in human use.(1) Nucleic acid vaccines require a short time from design to clinical trials; therefore, it may be possible to test together, in t…”
Jenkin, D., Ritchie, A. J., Aboagye, J., Fedosyuk, S., Thorley, L., Provstgaard-Morys, S., Sanders, H., Bellamy, D. G., Makinson, R., Xiang, Z., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00126-4 · Cited by 37
“30,31 In our view, clinical evaluation of a nucleoside-modified mRNA rabies vaccine is worthwhile.”
CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864298 · Cited by 35
“BNT162b2 for preventing SARS-CoV-2 was 95% (130).”
Carazo, S., Talbot, D. C., Boulianne, N., Brisson, M., Gilca, R., Deceuninck, G., Brousseau, N., Drolet, M., Ouakki, M., Sauvageau, C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab739 · Cited by 36
Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report
Lensen, R., Netea, M. G., & Rosendaal, F. R. (2021) · International Medical Case Reports Journal · doi:10.2147/imcrj.s328482 · Cited by 31
Long COVID Risk and Pre-COVID Vaccination: An EHR-Based Cohort Study from the RECOVER ProgramPreprint
Brannock, M. D., Chew, R., Preiss, A., Hadley, E., McMurry, J. A., Leese, P., Girvin, A. T., Crosskey, M., Zhou, A., Moffitt, R. A., et al. (2022) · medRxiv · doi:10.1101/2022.10.06.22280795 · Cited by 31
“It is well-documented that vaccination reduces the risk of developing COVID-19, 6,7 offering one mechanism for preventing Long COVID.”
Feng, A., Obolski, U., Stone, L., & He, D. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001211 · Cited by 33
“1 as 1 minus the approximate short term vaccine efficacy (~90%) estimated from the original vaccine randomized control trials (4) (in the other words, the immediate risk of infection shortly after second dose vaccination is 10%).”
Evaluation of the United States COVID-19 vaccine allocation strategy
Islam, M. R., Oraby, T. F., McCombs, A., Chowdhury, M. M., Al-Mamun, M. A., Tyshenko, M. G., & Kadelka, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259700 · Cited by 38
“After clinical trials reported efficacy rates of around 95% [49, 50], initial data from the US vaccine roll-out found the Pfizer/BioNTech BNT162b2-mRNA and Moderna mRNA-1273 vaccines to be 90% effective [34].”
BackgroundStructural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
Cai, Y., Zhang, J., Xiao, T., et al. (2021) · bioRxiv · doi:10.1101/2021.04.13.439709 · Cited by 92
“Several of them have completed phase 3 trials, showing impressive protective efficacy with minimal side effects (31, 32), and they have therefore received Emergency Use Authorization (EUA) by various regulatory agencies throughout the world.”
BackgroundRoßmann, L., Bagola, K., Stephen, T., Gerards, A.-L., Walber, B., Ullrich, A., Schülke, S., Kamp, C., Spreitzer, I., Hasan, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103651118 · Cited by 35
DOCK2 regulates antifungal immunity by regulating RAC GTPase activity
Ma, X., Tan, X., Yu, B., Sun, W., Wang, H., Hu, H., Du, Y., He, R., Gao, R., Peng, Q., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00835-0 · Cited by 32
“Through the development of an in vivo RNA delivery system and the progress in RNA modifications to avoid stimulating the immune response, RNA-based drugs or vaccines have achieved great success in treating genetic diseases and preventing infectious diseases [43, 53, 54].”
BackgroundValentin, A., Bergamaschi, C., Rosati, M., Angel, M., Burns, R., Agarwal, M., Gergen, J., Petsch, B., Oostvogels, L., Loeliger, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945706 · Cited by 34
“This dichotomy has already been noticed with other mRNAbased vaccines in certain studies reporting low antigen-specific T cell responses in blood of macaques and humans (35, 55, 57, 59, 60, 63, 64, 84).”
COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis
Chou, O. H. I., Mui, J., Chung, C. T., Radford, D., Ranjithkumar, S., Evbayekha, E. O., Nam, R. H. K., Pay, L., Satti, D. I., García-Zamora, S., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02070-7 · Cited by 34
“The landmark trials of COVID-19 vaccinations demonstrated favourable safety profiles with complications being rarely reported, with no cases of post-vaccine myocarditis or pericarditis being observed [27, 28].”
BackgroundRhim, J. W., Kang, J.-H., & Lee, K. (2021) · Korean Journal of Pediatrics · doi:10.3345/cep.2021.01270 · Cited by 34
Strategies for fighting pandemic virus infections: Integration of virology and drug delivery
Nakamura, T., Isoda, N., Sakoda, Y., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.046 · Cited by 32
SARS -CoV-2 T-cell immunity to variants of concern following vaccination
Gallagher, K. M. E., Leick, M. B., Larson, R. C., Berger, T. R., Katsis, K., Yam, J. Y., Brini, G., Grauwet, K., MGH COVID-19 Collection & Processing Team, & Maus, M. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442455 · Cited by 31
The variants question: What is the problem?
Zella, D., Giovanetti, M., Benedetti, F., Unali, F., Spoto, S., Guarino, M. P. L., Angeletti, S., & Ciccozzi, M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27196 · Cited by 30
Nadeem, I., Munamm, S. A. U., Rasool, M. U., Fatimah, M., Bakar, M. A., Rana, Z. K., Khatana, U., Jordon, L., Saqlain, M., Mahdi, N., et al. (2022) · Postgraduate medical journal · doi:10.1136/postgradmedj-2022-141649 · Cited by 30
Elia, U., Rotem, S., Bar‐Haim, E., Ramishetti, S., Naidu, G. S., Gur, D., Aftalion, M., Israeli, M., Bercovich-Kinori, A., Alcalay, R., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01284 · Cited by 31
Kumar, M., Kumari, N., Thakur, N., Bhatia, S. K., Saratale, G. D., Ghodake, G. S., Mistry, B. M., Alavilli, H., Kishor, D. S., Du, X., et al. (2021) · Plants · doi:10.3390/plants10061213 · Cited by 35
Isa, F., Forleo‐Neto, E., Meyer, J., Zheng, W., Rasmussen, S., Armas, D. R., Oshita, M. H., Brinson, C. C., Folkerth, S., Faria, L., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.045 · Cited by 31
The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis
Sobczak, M., & Pawliczak, R. (2022) · Clinical and Molecular Allergy · doi:10.1186/s12948-022-00167-y · Cited by 32
“The results of phase 2/3 of randomized clinical trial of BNT162b2 vaccine showed that this vaccine has 95% efficiency against COVID-19 after full vaccination with two doses in participants older than 16 years [7].”
BackgroundMingyao, B., Tam, A. R., Chan, K. W., Ma, M. K. M., Hung, I. F., Yap, D. Y. H., & Chan, T. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.827859 · Cited by 33
“COVID-19 vaccination has proven efficacy in alleviating disease severity and reducing mortality in the general population (5), and hence effective immunization holds promise to minimize adverse outcomes in dialysis and kidney transplant patients infected by SARS-CoV-2.”
BackgroundInternal cap-initiated translation for efficient protein production from circular mRNA
Fukuchi, K., Nakashima, Y., Abe, N., Kimura, S., Hashiya, F., Shichino, Y., Liu, Y., Ogisu, R., Sugiyama, S., Kawaguchi, D., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02561-8 · Cited by 50
COVID-19 vaccination acceptance among Syrian population: a nationwide cross-sectional study
Shibani, M., Alzabibi, M. A., Mohandes, A. F., Alsuliman, T., Mouki, A., Ismail, H., Al-Hayek, S., Rmman, A. A., Mansour, M., Marrawi, M., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12186-6 · Cited by 36
“Perhaps because of newly introduced technologies, as it is the first time people learned about vaccines that use Messenger RNA was with the PfizerBiontech vaccine [42].”
BackgroundChen, R., Zhang, X., Yuan, Y., Deng, X., Wu, B., Xi, Z., Wang, G., Lin, Y., Li, R., Wang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202105378 · Cited by 32
Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review
Azeem, M., Cancemi, P., Mukhtar, F., Marino, S., Peri, E., Prima, G. D., & De, V. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123610 · Cited by 39
Heterogeneity in Spatial Inequities in COVID-19 Vaccination Across 16 Large US Cities
Bilal, U., Mullachery, P. H., Schnake-Mahl, A. S., Rollins, H., McCulley, E. M., Kolker, J., Barber, S., & Roux, A. V. D. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac076 · Cited by 30
“These vaccines have proven highly efficacious (6, 7) and effective (8), and represent one of the key tools to address the ongoing pandemic.”
BackgroundmRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation
Demongeot, J., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 42
“Lipid nanoparticles have been clinically studied for the delivery of small molecules, druglike siRNA [16] and mRNA [17–19], including two mRNAs, which have obtained conditional marketing authorization as vaccines against the coronavirus disease COVID-19, mRNA1273 [19] and BNT162b [20].”
BackgroundNotarte, K. I., Catahay, J. A., Peligro, P. J., et al. (2023) · Vaccines · doi:10.3390/vaccines11040724 · Cited by 31
“Further, randomized clinical trials for the BNT162b2 vaccine had included a few patients with kidney disease [8].”
BackgroundOptimal vaccine allocation for COVID-19 in the Netherlands: A data-driven prioritization
Miura, F., Leung, K. Y., Klinkenberg, D., Ainslie, K. E. C., & Wallinga, J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009697 · Cited by 30
“Note that we considered the unit of vaccines as a set of full doses; for example, the Pfizer vaccine needs to be administered twice, and the set of those two doses was defined as a single unit here.”
BackgroundInfluentialAyoub, H. H., Chemaitelly, H. S., Makhoul, M., Kanaani, Z. A., Al‐Kuwari, E., Butt, A. A., Coyle, P. V., Jeremijenko, A. M., Kaleeckal, A. H., Latif, A. N., et al. (2021) · BMJ Innovations · doi:10.1136/bmjinnov-2021-000677 · Cited by 33
Matkowska‐Kocjan, A., Owoc‐Lempach, J., Chruszcz, J., Kuźnik, E., Szenborn, F., Jurczenko, L., Wójcik, M., Banyś, D., Szenborn, L., & Ussowicz, M. (2021) · Vaccines · doi:10.3390/vaccines9101209 · Cited by 31
“vaccines were conducted mostly among generally healthy, non-immunocompromised individuals [3].”
BackgroundStankov, M. V., Cossmann, A., Bonifacius, A., Dopfer‐Jablonka, A., Ramos, G. M., Gödecke, N., Scharff, A. Z., Happle, C., Boeck, A.-L., Tran, A. T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab555 · Cited by 35
Clinical Cardiovascular Adverse Events Reported Post-COVID-19 Vaccination: Are They a Real Risk?
Hana, D., Patel, K. B., Roman, S., Gattas, B. S., & Sofka, S. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101077 · Cited by 36
“Innate response to mRNA vaccine products such as the lipid nanoparticles or other adjuvants is also unlikely as these have been shown to not result in an inflammatory or immune response.(3,2) In addition, cases of myocarditis and pericarditis have also been reported in the Janssen vaccine as well, which is not an mRNA…”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.